Accumulation of metabolic risk factors substantially increased risk for MACE in patients with recent ACS. Alirocumab treatment reduced MACE consistently, although absolute risk reduction was more pronounced in patients with multiple metabolic risk factors, including patients without diabetes (Ostadal P, et al. [Lancet Diabetes Endocrinol. 2022]).